Literature DB >> 10713873

A clinical comparison of ropivacaine 0.75%, ropivacaine 1% or bupivacaine 0.5% for interscalene brachial plexus anaesthesia.

A Casati1, G Fanelli, G Cappelleri, P Beccaria, L Magistris, B Borghi, G Torri.   

Abstract

In order to compare interscalene brachial plexus block performed with ropivacaine or bupivacaine, 45 healthy, unpremedicated patients, undergoing elective shoulder surgery, were randomly allocated to receive interscalene brachial plexus anaesthesia with 20 mL of either ropivacaine 0.75% (n = 15), ropivacaine 1% (n = 15), or bupivacaine 0.5% (n = 15). Readiness for surgery (loss of pinprick sensation from C4 to C7 and inability to elevate the limb from the bed) was achieved later with bupivacaine 0.5% (28 +/- 15 min) than with ropivacaine 1% (10 +/- 5 min) (P = 0.005) and ropivacaine 0.75% (15 +/- 8 min) (P = 0.0005). No differences in success rate were observed between the three groups; however, seven patients receiving bupivacaine 0.5% required intra-operative analgesic supplementation (fentanyl 0.1 mg intravenous) compared with one patient receiving ropivacaine 0.75%, and two patients treated with ropivacaine 1% (P = 0.02). The time from the block placement to first request for pain medication was similar in the three groups (10.7 +/- 2 h, 11 +/- 2.4 h, and 10.9 +/- 3.9 h after 0.75% and 1% ropivacaine or 0.5% bupivacaine, respectively). We conclude that interscalene brachial plexus block performed with 20 mL of either 0.75% or 1% ropivacaine allows for a prolonged post-operative pain relief, similar to that provided by bupivacaine 0.5%, with short onset time of surgical anaesthesia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10713873     DOI: 10.1046/j.1365-2346.1999.00590.x

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  5 in total

Review 1.  Upper extremity regional anesthesia: essentials of our current understanding, 2008.

Authors:  Joseph M Neal; J C Gerancher; James R Hebl; Brian M Ilfeld; Colin J L McCartney; Carlo D Franco; Quinn H Hogan
Journal:  Reg Anesth Pain Med       Date:  2009 Mar-Apr       Impact factor: 6.288

2.  Comparison of 0.25% levobupivacaine and 0.25% bupivacaine for posterior approach interscalene brachial plexus block.

Authors:  Semih Baskan; Vildan Taspinar; Levent Ozdogan; Kemal Yetis Gulsoy; Gulcan Erk; Bayazit Dikmen; Nermin Gogus
Journal:  J Anesth       Date:  2010-02       Impact factor: 2.078

3.  Rebound pain scores as a function of femoral nerve block duration after anterior cruciate ligament reconstruction: retrospective analysis of a prospective, randomized clinical trial.

Authors:  Brian A Williams; Matthew T Bottegal; Michael L Kentor; James J Irrgang; John P Williams
Journal:  Reg Anesth Pain Med       Date:  2007 May-Jun       Impact factor: 6.288

4.  Population pharmacokinetics of bupivacaine in combined lumbar and sciatic nerve block.

Authors:  Hanene Eljebari; Nadia Jebabli; Issam Salouage; Emna Gaies; Mohamed Lakhal; Mehdi Boussofara; Anis Klouz
Journal:  Indian J Pharmacol       Date:  2014 Mar-Apr       Impact factor: 1.200

5.  A double-blind randomized controlled trial comparing dexamethasone and clonidine as adjuvants to a ropivacaine sciatic popliteal block for foot surgery.

Authors:  Kris Vermeylen; Joris De Puydt; Stefan Engelen; Eva Roofthooft; Filiep Soetens; Arne Neyrinck; Marc Van de Velde
Journal:  Local Reg Anesth       Date:  2016-05-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.